Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Atypical Chronic Myeloid Leukemia: early-phase trial registry

2 of 5 indexed Atypical Chronic Myeloid Leukemia trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

5 US clinical trials · 2 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Atypical Chronic Myeloid Leukemia: 5 US clinical trials tracked, 2 recruiting.

Atypical Chronic Myeloid Leukemia is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Omar Aljitawi, running 1 of these trials.

Enrollment posture brief

Registry condition atypical-chronic-myeloid-leukemia

OPEN 2 | RECR 40% | LATE 0 | EARLY 5 | RANK #3391 | SPON 1

Nearest open-share peer: Achondroplasia (40% recruiting · 10 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Atypical Chronic Myeloid (th…40%
Open-enrollment share among volume-matched conditions near Atypical Chronic Myeloid Leukemia

Atypical Chronic Myeloid Leukemia lists 2 open slots (40% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Atypical Chronic Myeloid Leukemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Atypical Chronic Myeloid Leukemia is recruiting below its size-band peers.

    2 of 5 indexed trials (40%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Atypical Chronic Myeloid Leukemia research.

    Omar Aljitawi accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Most Atypical Chronic Myeloid Leukemia trials plan to enrol fewer than 100 people.

    Median target enrolment is 33 among the 5 trials that report a genuine target (sentinel values excluded). 4 of those (80%) plan for fewer than 100 participants.

  4. Atypical Chronic Myeloid Leukemia research is mostly interventional.

    5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 23

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 3

Named interventions

Most-linked intervention names on Atypical Chronic Myeloid Leukemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

beclomethasone dipropionate Drug
1 trials
methotrexate Drug
1 trials
Topotecan Hydrochloride Drug
1 trials
Allogeneic CD34+ selected stem cells Procedure
1 trials
conditioning regimen Drug
1 trials
Geriatric assessment (GA) pre-transplant Other
1 trials
allogeneic hematopoietic stem cell transplantation Procedure
1 trials
Veliparib Drug
1 trials

US sites by state

Facility locations filed on Atypical Chronic Myeloid Leukemia trials. A trial with sites in several states counts in each.

New Jersey 3 trials
New York 2 trials
Washington 1 trials
Ohio 1 trials
North Carolina 1 trials
Maryland 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Atypical Chronic Myeloid Leukemia page

5 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 2 Atypical Chronic Myeloid Leukemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Omar Aljitawi sponsors the most Atypical Chronic Myeloid Leukemia trials on record, review their full trial history before evaluating a specific study. See Omar Aljitawi's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Atypical Chronic Myeloid Leukemia condition card totals 5 registered trials; most-linked intervention beclomethasone dipropionate; top US site state New Jersey. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.